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Abstract
The prognosis of patients suffering from pancreatic cancer is still poor and novel therapeutic options are urgently
needed. Recently, the transcription factor signal transducer and activator of transcription 5b (STAT5b) was asso-
ciated with tumor progression in human solid cancer. Hence, we assessed whether STAT5b might serve as an
anticancer target in ductal pancreatic adenocarcinoma (DPAC). We found that nuclear expression of STAT5b
can be detected in approximately 50% of DPAC. Blockade of STAT5b by stable shRNA-mediated knockdown
showed no effects on tumor cell growth in vitro. However, inhibition of tumor cell motility was found even in response
to stimulation with epidermal growth factor or interleukin-6. These findings were paralleled by a reduction of prometa-
static and proangiogenic factors in vitro. Subsequent in vivo experiments revealed a strong growth inhibition on
STAT5b blockade in subcutaneous and orthotopic models. These findings were paralleled by impaired tumor angio-
genesis in vivo. In contrast to the subcutaneousmodel, the orthotopicmodel revealed a strong reduction of tumor cell
proliferation that emphasizes the meaning of assessing targets in an appropriate microenvironment. Taken together,
our results suggest that STAT5b might be a potential novel target for human DPAC.
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Introduction
Ductal pancreatic adenocarcinoma (DPAC) is one of the major leading
causes of cancer-related death in the Western world [1]. As conven-
tional cancer treatments have little impact on disease course, almost
all patients diagnosed with pancreatic cancer eventually develop metas-
tases and die [2,3]. To date, only surgical resection (possible in about
10–20% of patients) can increase the 5-year survival rate from almost
0% to 20%; systemic chemotherapy and/or radiation may only allow a
marginal increase in survival [4]. Therefore, new therapies based on the
molecular biology of pancreatic cancer are urgently needed to improve
overall survival of patients with this aggressive disease.
Activation of several signaling pathways and transcription factors is
commonly seen in human malignant tumors, including pancreatic
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cancer [4,5]. Among these factors, signal transducers and activators
of transcription (STATs) comprise a family of seven transcription
factors (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and
STAT6) and at least STAT3, STAT5a, and STAT5b are implicated
in solid tumor growth [6,7]. In particular, STAT3 has been involved
in angiogenesis, metastases, and apoptosis in various cancer entities,
including pancreatic cancer [8–10]. Regarding STAT5a, this tran-
scription factor has been reported to be involved in apoptosis of
breast cancer cells and a dominant-negative STAT5a mutant showed
induction of cell death and reduced invasive properties of prostate
cancer cells [11–14]. In contrast, STAT5b has been associated with
advanced tumor stage in colorectal cancer, glioblastoma, and hepato-
cellular carcinoma [15–18]. Moreover, experimental data suggest
a role for STAT5b in apoptosis and epithelial-mesenchymal transi-
tion [15,19]. In ovarian cancer, Chen et al. also describe a role for
STAT5 activation and angiogenesis [20]. However, little is known
about the effects of STAT5a and STAT5b in pancreatic cancer.
So far, some reports indicate a role for STAT5a in the development
of endocrine pancreatic diseases, e.g., diabetes [21], whereas STAT5b
has been shown to be expressed in intraductal papillary mucinous
neoplasms [22]. The role of STAT5b in human DPAC remains to
be determined.
In the present study, we show that nuclear expression of STAT5b
occurs in about half of DPACs investigated. Furthermore, experi-
mental knockdown of STAT5b expression in pancreatic cancer cells
led to strong inhibition of tumor growth in subcutaneous and ortho-
topic tumor models, which was linked to impaired angiogenesis. In
addition, down-regulation of STAT5b diminished tumor cell motil-
ity in vitro and impaired metastasis formation in vivo. STAT5b,
therefore, represents an interesting novel target for anticancer therapy
in pancreatic cancer.
Materials and Methods
Immunohistochemical Assessment of STAT5b Expression in
Human DPAC
To study the expression of STAT5b in human DPAC, we obtained
tumor specimens from patients who underwent surgery for pancreatic
adenocarcinoma between 2000 and 2008 in the Department of
Surgery, University Hospital Regensburg, Germany. Representative
formalin-fixed, paraffin-embedded tissue sections of 80 DPACs of
various tumor stages were immunostained using a STAT5b-specific
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Slides were
deparaffinized in xylene, followed by treatment with a graded series
of alcohol washes [100%, 96%, 70% ethanol/ddH2O (vol/vol)],
rehydration in phosphate-buffered saline (pH 7.5), and blocked
against endogenous peroxidase with H2O2. Slides were incubated
with primary antibody (1:25 dilution) at 4°C overnight. After wash-
ing with phosphate-buffered saline, biotinylated antibody (1:50 dilu-
tion; Vectastain Universal Elite ABC Kit, Vector Laboratories,
Burlingame, CA) was added to tissue sections. STAT5b was visualized
by Vectastain Elite ABC reagent (Vector Laboratories), followed
by incubation with DAB. Nuclei were counterstained with hema-
toxylin. Negative controls were performed by omitting the primary
antibody. Nuclear immunoreactivity for STAT5b was scored as
absent (−; <10% of cancer cells) or positive (+; >10% of cancer
cells) in accordance with a published scoring system for STAT5b
expression [22].
Cell Culture and Cytokines
The human pancreatic cancer cell line HPAF-II was obtained from the
American Type Culture Collection and L3.6pl cells were kindly provided
by Dr I. J. Fidler (The University of Texas M.D. Anderson Cancer
Center). Tumor cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; PAA Laboratories, Pasching, Austria) supplemented
with 15% fetal calf serum (FCS) and maintained in 5% CO2 at 37°C,
as described [23]. Recombinant human interleukin-6 (IL-6) and epi-
dermal growth factor (EGF) were purchased from R&D Systems
(Wiesbaden, Germany).
Stable Transfection
HPAF-II and L3.6pl cells were stably transfected with either
STAT5b-shRNA (TIB MOLBIOL, Berlin, Germany) or a luciferase-
shRNA (Luc-shRNA) expression plasmid by using Lipofectamin trans-
fection reagent (Invitrogen, Karlsruhe, Germany), as described before
[24]. Cells were maintained and expanded in selective medium contain-
ing neomycin (G418; Sigma Aldrich, Deisenhofen, Germany). Knock-
down of STAT5b was verified by Western blot analysis and by
polymerase chain reaction (PCR) for successful silencing. Two different
sequences for STAT5b knockdown were used for further experiments
to reduce potential off-target effects by certain sequences.
Measurement of Tumor Cell Growth In Vitro
To evaluate the effects of STAT5b, we seeded knockdown tumor
cells in 96-well plates (1 × 103 per well) for 24, 48, and 72 hours
under full medium and serum-reduced conditions (1%FCS inDMEM).
We used 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT)
assay to assess cell growth [25]. Effects of STAT5b inhibition on growth
of tumor cells in vitro were determined in a cell-counting assay. Briefly,
106 cells were seeded into six-well dishes; after 24, 48, and 72 hours, cells
were trypsinized and counted. Furthermore, [3H]thymidine assays were
used to assess proliferation inHPAF-II clones with STAT5b knockdown,
as previously described [26].
Migration Assays
To determine the effect of STAT5b inhibition on cell motility, we
performed migration assays using modified Boyden chambers [25].
Briefly, 5 × 104 tumor cells were resuspended in 1% FCS-DMEM
and seeded into inserts with 8-μm pores (Becton Dickinson Bio-
sciences, Heidelberg, Germany). EGF (50 ng/ml) and IL-6 (50 ng/ml)
were used as chemoattractants. Cells were fixed after 24 and 48 hours,
and migrated cells were stained (Diff-Quick reagent; Dade Behring,
Newark, NJ). Cells that migrated through the filters were counted in
four random fields and average numbers were calculated.
Western Blot Analyses
Experiments were performed at a cellular density of 60% to 70%.
Whole-cell lysates were prepared as described elsewhere [23,25]. Pro-
tein was prepared from tumor tissue for Western blot analyses [25].
Protein samples (40 μg) were subjected to Western blot analysis on a
denaturating 10% sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis. Membranes were sequentially probed to determine signaling
intermediates with antibodies against phospho-AKTSer473, Akt, c-Myc,
phospho-STAT3Tyr705, STAT3, Bim, Caspase-3, Puma, phospho-
BadSer136, Bad (Cell Signaling Technology, Beverly, MA), and
STAT5b and β-actin (Santa Cruz Biotechnology). Antibodies were
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detected by enhanced chemiluminescence (Amersham Biosciences,
Piscataway, NJ).
Real-time PCR Analysis
PCR was used to determine the effects of STAT5b knockdown on
target genes. Total RNA was isolated using TRIzol reagent (Invitrogen)
and subsequently purified by ethanol precipitation. For each RNA sam-
ple, 1 μg of aliquot was reverse transcribed into cDNA using the Super-
script II Kit (Qiagen, Hilden, Germany). Selected primer pairs for PCR
were given as follows: STAT5b (5′-TGAAGGCCACCATCATCAG
and 3′-TGTTCAAGATCTCGCCACTG), caveolin-1 (CAV-1; 5′-
GAAAGAAGATGGGGGAGGAG and 3′-AAAGTCCCCAAAGG-
CAGAAT), urokinase-type plasminogen activator receptor (uPAR;
5′-GCCTTACCGAGGTTGTGTGT and 3′-GCTTCGGGAA-
TAGGTGACAG), IL-6 (5′-CCCAGTACCCCCAGGAGAAGA
and 3′-GTTGGGTCAGGGGTGGTTATTG), hypoxia-inducible
factor–1α (HIF-1α; 5′-TACCATGCCCCAGATTCAGGAT and 3′-
TCAGTGGTGGCAGTGGTAGTGG), vascular endothelial growth
factor-A (VEGF-A; 5′-GCAGCTTGAGTTAAACGAACG and 3′-
GGTTCCCGAAACCCTGAG), vascular endothelial growth factor-D
(VEGF-D; 5′-GGTGCAGGCTCCAGTAATGA and 3′-AGGGCTT-
GAAGAATGTGTTG), and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; 5 ′-GCGGGGCTCCCAGAACATCAT and 3 ′-
CCAGCCCCAGCGTCAAAGGTG). Primers were optimized for
MgCl2 and annealing, and PCR products were confirmed by gel electro-
phoresis. Reverse transcription–PCR was performed by using the
LightCycler system and Roche FastStart LightCycler-Master Hybridiza-
tion Probes master mix (Roche Diagnostics, Mannheim, Germany).
Animal Models
Eight-week-old male athymic nude mice (BALB/cnu/nu; Charles
River, Sulzfeld, Germany) were used for experiments, as approved
by the Institutional Animal Care and Use Committee of the Univer-
sity of Regensburg and the regional authorities. In addition, experi-
ments were conducted according to the “Guidelines for the Welfare of
Animals in Experimental Neoplasia” published by the United Kingdom
Coordinating Committee on Cancer Research. Effects of selec-
tive STAT5b inhibition were first evaluated in a subcutaneous pan-
creatic cancer model using HPAF-II and L3.6pl pancreatic cancer
cells stably transfected with Luc-shRNA and two STAT5b-shRNA
vectors (different STAT5b inhibitory sequences). Cells (1 × 106) were
injected into the subcutis (right flank) of nude mice (n = 6–8/group).
Tumor diameters were measured every other day and tumor volumes
were determined by using the formula width2 × length × 0.5. Sub-
cutaneous tumors were excised and weighed when the experiment
was terminated.
Subsequently, the effects of STAT5b inhibition were evaluated in
an orthotopic tumor model. Briefly, 1 × 106 HPAF-II human pan-
creatic cancer cells (Luc-shRNA–transfected cells and STAT5b-
shRNA–transfected cells) were injected into the pancreatic tail of
mice (n = 5–6/group). Mice were sacrificed after 32 days; tumors
were excised and weighed, and the incidence of liver and lymph node
metastases was determined. Tumors were either paraffin-embedded
or ornithine carbamoyltransferase–embedded for immunohistochem-
ical analyses or stored for protein extraction. Knockdown of STAT5b
in tumor cells was determined by Western blot analysis and PCR
before injection of tumor cells into mice. In addition, STAT5b expres-
sion was determined from tumor tissue after termination of the experi-
ments by Western blot analysis.
Immunohistochemical Analysis of Tumor Vascularization and
Tumor Cell Proliferation
Multiple cryosections were obtained from tumors for all immuno-
histochemical analyses. CD31+ vessel area was assessed using rat anti-
mouse CD31/PECAM-1 antibody (Pharmingen, San Diego, CA)
and peroxidase-conjugated goat anti-rat immunoglobulin G (IgG)
(Jackson Research Laboratories, West Grove, PA), as previously de-
scribed [27]. Antibody binding was visualized using stable DAB.
Images were obtained in four different quadrants of each tumor section
(2 mm inside the tumor–normal tissue interface) at 40× magnification.
The area of CD31-stained vessels was determined by converting images
to grayscale and setting a consistent threshold for all slides using ImageJ
software (version 1.33; National Institutes of Health). Vessel areas were
expressed as pixels per high-power field [25,27]. To define the amount
of proliferating tumor cells, mice received intraperitoneal injections
of bromodeoxyuridine (BrdU; Sigma Aldrich; 1 mg/mouse) 2 hours
before termination of animal studies. A commercially available BrdU
detection kit (Becton Dickinson) was used to visualize BrdU uptake
of cells in tumor sections. Briefly, sections were incubated with anti-
BrdU antibody solution, followed by streptavidin-conjugated HRP-
linked goat anti-mouse IgG2. Antibody binding was visualized by
incubating slides with DAB followed by hematoxylin counterstaining.
BrdU-positive tumor cells were counted in four fields per tumor section
at 20× magnification and averages were calculated [25].
For analyses of tumor cell apoptosis, a commercially available ter-
minal deoxynucleotidyl transferase–mediated deoxyuridine triphos-
phate nick end labeling (TUNEL) detection kit was used (Promega,
Mannheim, Germany). After the staining procedure, four fields at
20× magnification were selected in each tumor at the proliferation
front, and identifiable TUNEL-positive cells were counted.
Statistics
Statistical analyses were carried out by using SigmaStat (Version 3.0).
Results of in vivo experiments were analyzed for significant outliers
using the Grubb’s test (www.graphpad.com). Tumor-associated vari-
ables of in vivo experiments were tested for statistical significance using
the Mann-Whitney U test for nonparametric data or analysis of vari-
ance followed by Tukey’s multiple comparison tests for more than two
groups. The two-sided Student’s t test was applied for analysis of in vitro
data. Patient survival was determined using the Cox regression analyses.
All results are expressed as the mean ± SEM.
Results
STAT5b Is Expressed in DPAC
Because increased STAT5b expression was observed in intraduc-
tal papillary mucinous neoplasm progressing to intraductal papillary
mucinous carcinoma, we asked whether this transcription factor
might also play a role in DPAC. To evaluate this issue, we deter-
mined the expression of STAT5b protein by immunohistochemistry
in DPAC (Figure 1A ). Using a collection of 80 tumor samples,
42 tumors showed nuclear expression of STAT5b (>10% of cancer
cells). No association was found regarding tumor localization, histo-
logic grading, tumor stage, or lymph node stage (Table 1). Tumors
with nuclear positive STAT5b expression showed a trend (not sta-
tistically significant) toward reduced patient survival (Figure 1B ).
Furthermore, weak positive STAT5b staining was found in normal
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pancreatic ducts adjacent to the tumor tissue in some areas. In addi-
tion, some peritumoral stromal cells showed positive nuclear staining.
Nevertheless, results show that STAT5b is expressed in cancer cells in
about half of human DPACs, representing a potential target for anti-
cancer therapy.
Inhibition of STAT5b by Stable shRNA Vector in Pancreatic
Cancer Cell Lines Has No Effects on Growth of Tumor Cells
In Vitro
The effect of STAT5b inhibition on pancreatic cancer cell lines
was assessed. In the absence of a commercially available STAT5b
inhibitor, STAT5b-shRNA plasmids were used. After successful
transfection of HPAF-II and L3.6pl pancreatic cancer cell lines,
inhibition of STAT5b expression was determined by Western blot
analysis and PCR (Figure 2, A and B, for HPAF-II and Figures W1A
and W3A for L3.6pl). Stable transfection led to inhibition of
STAT5b expression in approximately 70% to 80% of HPAF-II
and L3.6pl pancreatic cancer cells. We next sought to evaluate the
impact of STAT5b inhibition on the growth of tumor cells in vitro.
Figure 1. STAT5b expression in human DPAC. (A) Left: Strong nuclear expression of STAT5b in the majority of cancer cells. Right: No
nuclear STAT5b expression in cancer cells. (B) Patients where nuclear STAT5b expression was present in >10% of cancer cells showed
a trend toward reduced survival as determined by Kaplan-Meier analysis. This did not reach statistical significance (P = 0.204).
Table 1. A Total of 80 Human DPACs Were Assessed for Nuclear STAT5b Expression.
Nuclear Immunoreactivity (Number of Patients)
Variable Number STAT5b Positive STAT5b Negative P value
Total 80 42 38
Sex
Male 52 27 25 1.0
Female 28 15 13
Localization
Pancreatic head 58 29 29 .6
Pancreatic tail 22 13 9
Histologic grading
G1 5 2 3 .8
G2 39 20 19
G3 36 20 16
pT stage
T1, T2 8 3 5 .5
T3, T4 72 39 33
N stage
N0 22 12 10 1.0
N1 58 30 28
No statistical differences were found regarding gender, localization, grading, pT stage, and lymph
node status.
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Interestingly, we found no difference between parental tumor
cells, Luc-shRNA–transfected tumor cells, and STAT5b-shRNA–
transfected tumor cells by MTT assays (HPAF-II and L3.6pl;
Figures 2C and W2A). These effects were confirmed by using a cell
counting method for both cancer cell lines (Figure W2, B and C ). In
addition, [3H]thymidine incorporation assays revealed no signif-
icant effects of STAT5b blockade on HPAF-II cell proliferation
with STAT5b knockdown (Figure W2D). However, when comparing
activation of signaling intermediates on STAT5b blockade, we detected
reduced phosphorylation of STAT3 and slightly reduced expression
of c-Myc (Figures 2D and W1B). Surprisingly, phosphorylation of
AKTSer473 was increased on STAT5b inhibition, indicating possible
activation of survival signaling in tumor cells. Nevertheless, results from
these experiments show that targeting STAT5b has no direct effect on
the growth of pancreatic cancer cells in vitro; we also conclude that
STAT5b inhibition influences various signaling pathways.
Impairment of Tumor Cell Motility by Down-regulation
of STAT5b
Because STAT5b is known to modulate migration and invasion of
tumor cells, we evaluated the effects of STAT5b inhibition on motility
of stably transfected pancreatic cancer cells [15,28]. Boyden chamber
Figure 2. Effects of targeting STAT5b on human pancreatic cancer cell line HPAF-II in vitro. (A and B) Knockdown of STAT5b in HPAF-II
pancreatic cancer cell line using an shRNA approach was verified by Western blot analysis (A) and PCR (B). STAT5b expression was
reduced by 70% to 80% as determined by both methods. (C) Knockdown of STAT5b in HPAF-II has no effects on the growth of tumor
cells in vitro, as determined by MTT assay. (D) Inhibition of STAT5b leads to a reduction of constitutive STAT3 phosphorylation and c-Myc
expression in HPAF-II cancer cells. However, phosphorylation of AKTSer473 was observed on STAT5b blockade in vitro. Results are shown
for HPAF-II pancreatic cancer cells; similar results were obtained from L3.6pl cells. Bars, SEM.
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assays show that inhibition of STAT5b leads to a significant reduction
in constitutive HPAF-II tumor cell migration (Figure 3A). In addition,
because IL-6 and EGF are both known to induce motility of pancreatic
cancer cell lines at least in part through activation of janus kinase (JAK)/
STAT signaling, the effect of STAT5b inhibition on IL-6– and EGF-
induced motility was determined. As previously shown, IL-6 and EGF
led to an increase in tumor cell motility that was impaired by knock-
down of STAT5b in the pancreatic cancer cell line HPAF-II (Figure 3,
B and C ). Similar results were obtained from L3.6pl pancreatic cancer
cells with stable STAT5b knockdown (data not shown). In summary,
down-regulation of STAT5b impairs constitutive and IL-6–/EGF-
induced motility of pancreatic cancer cell lines in vitro.
Regulation of Metastasis Mediators by STAT5b Inhibition
In view of the fact that STAT5b inhibition impairs tumor cell motil-
ity, we assessed whether it also affects the expression of prometastatic
factors CAV-1, uPAR, and VEGF-D [29–32]. Indeed, knockdown of
STAT5b led to a significant reduction of CAV-1 and uPAR mRNA
in HPAF-II cells (Figure 3, D and E ). Furthermore, expression of
VEGF-D was significantly reduced in the pancreatic cancer cell line
HPAF-II on STAT5b inhibition (Figure 3F ). These results were con-
firmed in L3.6pl human cancer cells stably transfected with STAT5b-
shRNA plasmid (Figure W3, B–D). We conclude that targeting
STAT5b may reduce tumor cell motility and impair expression of
prometastatic factors in tumor cells.
Ef fects of Targeting STAT5b on Mediators of
Tumor Angiogenesis
Because the role of STAT5b in pancreatic cancer angiogenesis has
not been investigated, we determined the impact of STAT5b on angio-
genic factors. We found a slight, but significant, reduction of HIF-1α
expression in one of the two HPAF-II STAT5b-shRNA knockdown
Figure 3. Targeting STAT5b in pancreatic cancer cell line HPAF-II impairs tumor cell motility and modulates mediators of metastases.
(A) Inhibition of STAT5b by shRNA results in a significant decrease in constitutive tumor cell motility in vitro (*P< .05). Results are shown
for two HPAF-II clones with stable STAT5b knockdown. (B) Stimulation with IL-6 leads to an increase in HPAF-II motility (#P< .05). Knock-
down of STAT5b impairs both constitutive and IL-6–induced migration (*, **P< .05). (C) Similar to IL-6, EGF induces HPAF-II cell motility
(#P < .05). This effect is blocked by knockdown of STAT5b (*, **P < .05). (D–F) Stable shRNA-mediated knockdown of STAT5b sig-
nificantly reduces mRNA expression of metastatic factors CAV-1, uPAR, and VEGF-D in the human pancreatic cancer cell line HPAF-II
(*P < .05). All results are shown for HPAF-II human pancreatic cancer cells; similar results were obtained from L3.6pl cells. Bars, SEM.
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clones (Figure 4A). More consistently, a significant reduction of IL-6
and VEGF-A mRNA was detected in both HPAF-II STAT5b-shRNA
clones (Figure 4, B and C ). This observation was further supported by
the significant reduction of VEGF-A secretion from tumor cells as
determined by ELISA (Figure 4D). Nevertheless, effects on HIF-1α
expression were not found in L3.6pl STAT5b-shRNA–transfected
cells, whereas reduction of IL-6 and VEGF-A mRNA, as well as
VEGF-A secretion, was confirmed (FigureW3, E–H ). Taken together,
specific inhibition of STAT5b may also affect tumor angiogenesis
through effects on VEGF-A secretion rather than effects on HIF-1α
expression in pancreatic cancer cells.
Impact of STAT5b Down-regulation on
Tumor Growth In Vivo
The effects of STAT5b inhibition on tumor growth in vivo were
first determined in subcutaneous tumor models. While HPAF-II
cells with Luc-shRNA (control vector transfected) showed exponen-
tial growth (Figure 5A), inhibition of STAT5b significantly impaired
tumor growth in both HPAF-II STAT5b-shRNA clones tested
(STAT5b clone 1 and STAT5b clone 2; Figure 5A ). After 21 days,
control mice and STAT5b clone 1 mice were sacrificed and the weight
of STAT5b clone 1 tumors was found to be significantly reduced
(Figure 5C ). Similar results were obtained with L3.6pl cells with stable
STAT5b-shRNA–induced knockdown (Figure W4, A and B ). To fur-
ther evaluate the duration of growth inhibition in HPAF-II cells by
STAT5b knockdown, the second clone was continued in mice. Results
show that these tumors started growing after around 5 weeks (Fig-
ure 5A ). Western blot analyses of STAT5b expression in tumor
tissue showed that STAT5b was not detectable in STAT5b clone 1,
whereas control vector–transfected cells had strong STAT5b ex-
pression. In contrast, the STAT5b clone 2 continued until regrowth
had detectable STAT5b expression; however, the overall STAT5b
protein level was lower than in the control vector–transfected tumors
(Figure 5B). We conclude from these results that the STAT5b inhibi-
tion was sufficient to impair tumor growth in vivo and that regrowth
of tumors is at least in part due to loss of the STAT5b knockdown
plasmid from the tumor cells. It is also possible that escape mechanisms
associated with STAT5b inhibition might play a role.
The effects of STAT5b on tumor cell proliferation, angiogenesis,
and apoptosis in vivo were determined by BrdU, CD31, and TUNEL
staining in tissue obtained from control vector–transfected and
STAT5b clone 1–derived tumors. Consistent with our in vitro results,
no difference regarding tumor cell proliferation (BrdU) and apoptosis
(TUNEL) was observed (Figure 5, D and E ). In contrast, tumor
angiogenesis as determined by CD31 vessel area was significantly re-
duced on STAT5b inhibition (Figure 5F ).
Effects of STAT5b Inhibition in an Orthotopic
Pancreatic Cancer Model
Because the microenvironment has a strong impact on tumor
growth, we next assessed the effects of STAT5b inhibition in an
orthotopic tumor model using HPAF-II pancreatic cancer cells stably
Figure 4.Modulation of angiogenic factors on STAT5b blockade. (A) A significant reduction of HIF-1αmRNA was only observed in one of
the HPAF-II STAT5b knockdown clones tested (*P < .05). (B) Inhibition of STAT5b leads to a significant reduction of IL-6 mRNA expres-
sion in HPAF-II pancreatic cancer cells (*P < .05). (C) Importantly, VEGF-A mRNA was markedly reduced in both HPAF-II STAT5b clones
investigated (*P < .05). (D) These results were confirmed by significant reduction of VEGF-A secretion from HPAF-II cancer cells in vitro
(*P < .05). All results are shown for HPAF-II human pancreatic cancer cells; results for L3.6pl cells are shown in Figure W3. Bars, SEM.
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transfected with control vector and STAT5b-shRNA plasmid. After
31 days, mice were sacrificed and tumors were excised. Similar to the
subcutaneous model, we found a significant inhibition of tumor
growth in vivo as determined by final tumor weight (Figure 6A ).
Western blot analyses from tumor tissue confirmed persistent STAT5b
knockdown when the experiment was terminated (Figure 6B). Interest-
ingly, growth inhibition was paralleled by a trend toward reduced
metastases in STAT5b knockdown tumors, although this did not reach
statistical significance (lymph node: two of six positive in controls, zero of
five positive in STAT5b-shRNA clone 1; liver: three of six positive in
controls, zero of five positive in STAT5b-shRNA clone 1). Results from
our experiments indicate that inhibition of STAT5b in pancreatic cancer
cells has strong inhibitory effects on orthotopic tumor growth in vivo.
To further assess whether inhibition of STAT5b has effects on tumor
cell proliferation, apoptosis and angiogenesis in the orthotopic model,
BrdU, TUNEL, and CD31 stainings were performed in relevant tissue
Figure 5. Inhibition of tumor growth on STAT5b knockdown in the subcutaneous tumor model (HPAF-II). (A) Stable shRNA-mediated
knockdown of STAT5b leads to a significant inhibition of tumor growth as determined in a subcutaneous tumor model. Results are
shown for two different shRNA sequences to avoid possible off-target effects. Starting from day 15 after tumor cell inoculation, tumors
in both groups with shRNA-mediated STAT5b knockdown were significantly smaller than control vector–transfected tumors (*P < .05).
Animals injected with STAT5b-shRNA clone 2 cells were left until tumor progression was observed. (B) Western blot analyses from
tumor tissue showed no STAT5b expression in STAT5b clone 1 compared to control vector–transfected tumors. In contrast, in STAT5b
clone 2 continued until regrowth, STAT5b expression was detectable at lower levels compared to controls. (C) Animals with control
tumors and STAT5b-shRNA clone1 tumors were sacrificed after 21 days. Inhibition of tumor growth was reflected by final tumor weight
(*P < .05). (D) Cell proliferation as measured by BrdU showed no difference between the control and STAT5b clone 1 tumors. (E) Fur-
thermore, the number of apoptotic (TUNEL-positive) cells was not different between control and STAT5b clone 1 tumors. (F) Inhibition of
STAT5b leads to a significant reduction of tumor vascularization as determined by CD31 vessel area (*P < .05). Bars, SEM.
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sections. Unexpectedly, tumor cell proliferation was significantly
impaired in the orthotopic model, which contrasts with our data from
in vitro experiments and from the subcutaneous tumor model that
showed no difference between luciferase-transfected control cells
and the STAT5b clone 1 (Figure 6C). In line with the subcutaneous
model results, no effect on tumor cell apoptosis was found (Figure 6D)
and no difference was detected (Western blot analysis) concerning the
expression of apoptotic markers Puma, Caspase 3, Bim, phospho-
BadSer136, and Bad (data not shown). Also consistent with the sub-
cutaneous model, vessel area (CD31 staining) was significantly reduced
on STAT5b inhibition (Figure 6E ). These results indicate that in-
hibition of STAT5b impairs pancreatic cancer growth through anti-
angiogenic mechanisms in vivo. Conflicting results regarding in vitro
versus in vivo tumor cell proliferation suggest that the in vivo pan-
creatic microenvironment may have a yet unknown role that enhances
STAT5b involvement.
Discussion
The prognosis of patients with DPAC remains poor with an overall
5-year survival rate below 2%. In general, pancreatic cancer is refrac-
tory to chemotherapy and radiotherapy. To date, only surgical re-
section provides increased tumor control, but overall survival rates
are still very poor [4]. Therefore, novel therapeutic approaches based
on the molecular biology of pancreatic cancer are urgently needed
to improve the prognosis for these patients. Within the present study,
we investigated STAT5b as a potential target for antineoplastic ther-
apy in pancreatic cancer models. Our results show that STAT5b is
expressed in half of the patient DPAC specimens. In preclinical mod-
els, specific knockdown of STAT5b in pancreatic cancer cell lines led
to strong inhibition of tumor growth and a decrease of metastatic
potential in vitro and in vivo. Together, our results suggest that
STAT5b might be a novel interesting target to improve outcome of
patients with pancreatic cancer.
Figure 6. Effects of STAT5b blockade in an orthotopic tumormodel. (A) Orthotopic implantation of HPAF-II pancreatic cancer cells into the
pancreatic tail of nude mice results in inhibition of tumor growth after 31 days, as determined by final tumor weight (*P< .05). (B) STAT5b
knockdown was persistent after 31 days (Western blot analysis). (C) Blockade of transcription factor STAT5b leads to a significant re-
duction in tumor cell proliferation (BrdU incorporation; *P < .05). (D) No effect was observed on tumor cell apoptosis (TUNEL staining).
(E) However, tumor vascularization, measured by CD31 vessel area, was reduced on STAT5b inhibition (*P < .05). Bars, SEM.
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Although several studies have investigated the expression of
STAT5b in solid cancers [16,17,22], the function of STAT5b in
human DPAC has not been addressed. With regard to pancreatic
malignancies, Kataoka et al. have shown increased nuclear expression
of STAT5b in intraductal papillary mucinous carcinoma compared
to intraductal papillary mucinous adenoma and normal pancreatic
ducts [22]. In the present study, we found that about half of DPACs
stain positive for nuclear STAT5b. Expression of STAT5b has been
associated with poor prognosis or advanced tumor stage in several solid
tumor entities including colon cancer, hepatocellular carcinoma, and
glioblastoma multiforme [15–18], but our exploratory clinical study
could not confirm this statistically regarding DPAC. However, even
with our limited patient numbers, a trend toward reduced survival
was evident in patients with nuclear STAT5b expression. We empha-
size caution when interpreting these results because of the small num-
ber of cases included into the study. Furthermore, tumor samples were
obtained from surgical resections with curative intents and one might
speculate that STAT5b expression is stronger in advanced stages where
resections are not performed anymore. Nevertheless, our results clearly
show that STAT5b is expressed in a subset of DPAC and therefore
might serve as a target for anticancer therapy.
Tumor growth cannot be sustained unless the supply of oxygen
and nutrients is assured by the formation of new blood vessels
[33,34]. Although pancreatic cancer is characterized by low vascular
density, induction of tumor angiogenesis is still essential for this
tumor entity. In particular, secretion of VEGF-A from tumor cells
is an important factor for development of new vessels [35,36], and
VEGF-A has been associated with a poor prognosis in DPAC [37–39].
Interestingly, we found a significant reduction of VEGF-A produc-
tion in tumor cells on STAT5b inhibition in vitro, which was paralleled
by a clear reduction of vessel area in subcutaneous and orthotopic
mouse models. These results are in line with previous reports from
Chen et al. that described a connection between STAT5 activation
and VEGF expression in ovarian cancer [20]. However, no discrimi-
nation between STAT5a and STAT5b was performed in their study.
Moreover, Liang et al. found a reduction of VEGF-A secretion from
glioblastoma multiforme cells on STAT5b inhibition, but their find-
ings were not evaluated in vivo [16]. In summary, our results show that
inhibition of STAT5b in pancreatic cancer cells has the potential to
diminish tumor growth at least in part through effects on VEGF-A
and tumor angiogenesis.
Metastasis formation in DPAC is a major issue because patients
either present with metastatic disease or very quickly develop metas-
tases even after curative resection [3,40]. Although several reports
have connected STAT5b expression to motility and metastasis in
solid tumor entities, this had not yet been investigated in DPAC
[15,16,18,41]. In glioblastoma multiforme, reduction of cancer cell
invasiveness by STAT5b inhibition was linked to reduction of FAK
expression [16]; in hepatocellular carcinoma, Lee et al. found that
STAT5b is essential for epithelial-mesenchymal transition associated
with metastasis formation [15,19]. Results from our study further
support the function of STAT5b as a modulator of tumor cell mo-
tility, even in response to various stimuli. Moreover, we found a re-
duction of prometastatic factors CAV-1, uPAR, and VEGF-D on
STAT5b inhibition [29,30,32]. These in vitro data are consistent
with the fact that we found no liver or lymph node metastases in
the orthotopic pancreatic cancer model on STAT5b blockade. Our
results provide strong indications that STAT5b plays a role in metas-
tasis formation in DPAC.
An important addition to present knowledge was our STAT5b
blockade in an orthotopic pancreatic cancer model, where we observed
significant growth inhibition similar to the subcutaneous mouse model
(Figures 5 and 6). Interestingly, analyses of the tumor tissue from the
orthotopic model revealed a strong antiproliferative effect of STAT5b
blockade, which was not observed in vitro or in the subcutaneous
model. One can speculate that inhibition of STAT5b in tumor cells
modulates the local pancreatic microenvironment, which in turn leads
to reduced tumor cell proliferation and therefore emphasizes the need
to verify results in appropriate orthotopic mouse models as proposed
recently [42]. However, we observed constitutive phosphorylation of
Akt, a known promoter of survival and proliferation in tumor cells,
on STAT5b blockade in vitro [43]. This might indicate a potential
escape mechanism from STAT5b-mediated growth inhibition at least
in our cell culture experiments. Nevertheless, these findings clearly
warrant further investigation.
In conclusion, we provide evidence that STAT5b is frequently
expressed in DPAC. Furthermore, we show that STAT5b is as an
interesting target to impair tumor growth and metastasis formation
in this devastating disease, at least in part through effects on tumor
vascularization. Therefore, inhibitors to STAT5b in pancreatic can-
cer should be tested as soon as they are available in preclinical and
clinical settings.
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Figure W1. Effects of targeting STAT5b on signaling in the L3.6pl
human pancreatic cancer cell line in vitro. (A) Knockdown of
STAT5b in L3.6pl human pancreatic cancer cells using an shRNA
approach was verified by Western blot analysis. (B) Inhibition of
STAT5b leads to a reduction of constitutive STAT3 phosphory-
lation and c-Myc expression in cancer cells. Phosphorylation of
AKTSer473 was observed on STAT5b blockade in vitro.
Figure W2. Effects of STAT5b knockdown on growth of pancreatic cancer cell lines in vitro. (A) Knockdown of STAT5b in L3.6pl has no
effects on the growth of tumor cells in vitro, as determined by MTT assay. (B and C) No inhibition of growth was observed in cell count
assays up to 72 hours for HPAF-II and L3.6pl cells. (D) [3H]thymidine incorporation assays did not show a significant inhibition of tumor
cell proliferation up to 96 hours for HPAF-II cells with stable STAT5b knockdown compared to controls. Bars, SEM.
Figure W3. Targeting STAT5b affects metastasis and angiogenesis mediators in L3.6pl human pancreatic cancer cells. (A) shRNA-
mediated knockdown of STAT5b was verified by PCR (L3.6pl cells). (B–D) Stable shRNA-mediated knockdown of STAT5b significantly
reduces mRNA expression of metastatic factors CAV-1, uPAR, and VEGF-D in L3.6pl pancreatic cancer cells (*P < .05). (E) No effects of
STAT5b on HIF-1α mRNA expression were observed in L3.6pl pancreatic cancer cells. (F) Inhibition of STAT5b leads to a significant IL-6
mRNA expression reduction in L3.6pl cells (*P < .05). (G) VEGF-A mRNA was significantly reduced in L3.6pl STAT5b knockdown clones
(*P < .05). (H) Decreased VEGF-A secretion was confirmed at a protein level (ELISA) in L3.6pl cells in vitro (*P < .05). Bars, SEM.
Figure W4. Subcutaneous L3.6pl pancreatic cancer tumor model
growth is inhibited on STAT5b knockdown. (A) Stable shRNA-
mediated knockdown of STAT5b leads to a significant inhibition
of subcutaneous tumor growth (*P < .05). (B) Growth inhibition
was reflected by final tumor weight (*P < .05).
